載入中
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
前收盤價
US$17.80
−US$0.82 · -4.40%
盤後
US$17.90
+US$0.10 · +0.56%
10月12日 下午7:52 ET
盤中時間採用ET。市場資料可能有所延遲。
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
日內區間
目前US$17.80
52週區間
目前US$17.80
盤中時間採用ET。市場資料可能有所延遲。
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
日內區間
目前US$17.80
52週區間
目前US$17.80
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 10.29億 USD | 6.27億 USD | 2.85億 USD | 1.17億 USD | 6882.6萬 USD |
| 銷貨成本 | 4.08億 USD | 2.35億 USD | 1.44億 USD | 6536.3萬 USD | — |
| 毛利 | 6.21億 USD | 3.93億 USD | 1.41億 USD | 5164.2萬 USD | 6882.6萬 USD |
| 研究與開發 | 4.15億 USD | 4.14億 USD | 3.82億 USD | 3.36億 USD | 3.13億 USD |
| 銷售、一般及管理費用 | 3.42億 USD | 2.84億 USD | 2.01億 USD | 1.74億 USD | 1.5億 USD |
| 營業費用 | 7.57億 USD | 6.96億 USD | 5.8億 USD | 5.07億 USD | 4.61億 USD |
| 利息收入 | 4010萬 USD | 6120.4萬 USD | 5448.7萬 USD | 818.2萬 USD | 97.1萬 USD |
| 利息支出 | 2140萬 USD | 2161.5萬 USD | 2179.4萬 USD | 1079.6萬 USD | 90萬 USD |
| 折舊和攤銷 | 2890萬 USD | 2335.9萬 USD | 2045.1萬 USD | 1839.2萬 USD | 1391.7萬 USD |
| 營業利益 | −1.37億 USD | −3.03億 USD | −4.39億 USD | −4.56億 USD | −3.92億 USD |
| 淨利 | −2.97億 USD | −1.77億 USD | −5.18億 USD | −4.46億 USD | −4.04億 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$61.00
上漲空間 242.70%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB2370.29萬0.22%108.2億 USD0.44%US$204.26-1.08%
iShares Core MSCI Emerging Markets ETFIEMG1555.35萬0.01%1602.49億 USD0.09%US$80.63-0.95%
Invesco Biotechnology & Genome ETFPBE1023.44萬2.43%4.22億 USD0.59%US$96.405-0.51%
iShares Core MSCI China ETF2801.HK687.01萬0.06%123.36億 HKD0.20%HK$23.24-0.43%
Tema Oncology ETFCANC363.14萬1.78%2.05億 USD0.99%US$40.5781-0.50%
iShares Core MSCI Asia ex Japan ETF3010.HK362.01萬0.01%339.43億 HKD0.28%HK$86.84-2.43%
iShares MSCI Emerging Markets ETFEEM345.52萬0.01%309.79億 USD0.72%US$66.15-0.97%
iShares MSCI China ETFMCHI340.01萬0.06%60.07億 USD0.59%US$52.15-0.76%iShares Biotechnology ETFIBBiShares Core MSCI Emerging Markets ETFIEMGInvesco Biotechnology & Genome ETFPBEiShares Core MSCI China ETF2801.HKTema Oncology ETFCANCiShares Core MSCI Asia ex Japan ETF3010.HKiShares MSCI Emerging Markets ETFEEMiShares MSCI China ETFMCHIAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
